Skip to content

In the BioHarmony Drug Report Database


Vitrakvi (larotrectinib) is a small molecule pharmaceutical. Larotrectinib was first approved as Vitrakvi on 2018-11-26. It is used to treat neoplasm drug resistance and neoplasm metastasis in the USA. It has been approved in Europe to treat abdominal neoplasms. It is known to target high affinity nerve growth factor receptor. Vitrakvi's patents are valid until 2037-04-04 (FDA).
Trade Name Vitrakvi
Common Name Larotrectinib
Indication abdominal neoplasms, neoplasm drug resistance, neoplasm metastasis
Drug Class Tyrosine kinase inhibitors: tropomyosin receptor kinase (TRK) inhibitors
Get full access now